SI1523496T1 - Rekombinantno proizvajanje zmesi protiteles - Google Patents

Rekombinantno proizvajanje zmesi protiteles

Info

Publication number
SI1523496T1
SI1523496T1 SI200332045T SI200332045T SI1523496T1 SI 1523496 T1 SI1523496 T1 SI 1523496T1 SI 200332045 T SI200332045 T SI 200332045T SI 200332045 T SI200332045 T SI 200332045T SI 1523496 T1 SI1523496 T1 SI 1523496T1
Authority
SI
Slovenia
Prior art keywords
mixtures
antibodies
nucleic acid
light chain
host cell
Prior art date
Application number
SI200332045T
Other languages
English (en)
Slovenian (sl)
Inventor
Berkel Patrick Hendrikus Cornelis Van
Ronald Hendrik Peter Brus
Abraham Bout
Ton Logtenberg
Original Assignee
Merus B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43768900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1523496(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus B V filed Critical Merus B V
Publication of SI1523496T1 publication Critical patent/SI1523496T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI200332045T 2002-07-18 2003-07-15 Rekombinantno proizvajanje zmesi protiteles SI1523496T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39706602P 2002-07-18 2002-07-18
EP02077953 2002-07-18
EPPCT/EP03/50201 2003-05-27
PCT/EP2003/007690 WO2004009618A2 (en) 2002-07-18 2003-07-15 Recombinant production of mixtures of antibodies
EP03764997A EP1523496B1 (en) 2002-07-18 2003-07-15 Recombinant production of mixtures of antibodies

Publications (1)

Publication Number Publication Date
SI1523496T1 true SI1523496T1 (sl) 2011-11-30

Family

ID=43768900

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332045T SI1523496T1 (sl) 2002-07-18 2003-07-15 Rekombinantno proizvajanje zmesi protiteles

Country Status (14)

Country Link
US (9) US7262028B2 (https=)
EP (2) EP2314629B2 (https=)
JP (4) JP4836451B2 (https=)
CN (3) CN100480260C (https=)
AT (1) ATE514717T1 (https=)
AU (2) AU2003250074B2 (https=)
CA (3) CA2872136C (https=)
CY (1) CY1111886T1 (https=)
DK (2) DK1523496T3 (https=)
ES (2) ES2368733T3 (https=)
NZ (1) NZ537277A (https=)
PT (2) PT1523496E (https=)
SI (1) SI1523496T1 (https=)
WO (1) WO2004009618A2 (https=)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) * 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
CA2756610C (en) * 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP2290100B1 (en) * 2002-11-01 2014-02-19 Iris International, Inc. Kits for displacement Sandwich Immuno-PCR
GB0230201D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Retargeting
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
WO2004065611A1 (ja) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
EP1626992B1 (en) * 2003-05-23 2010-06-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) * 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
EP1508576A1 (en) * 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
AU2011218688B2 (en) * 2004-05-27 2013-01-10 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
CN1961002B (zh) * 2004-05-27 2011-05-18 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
ES2332524T3 (es) * 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
DE602005023529D1 (de) * 2004-11-03 2010-10-21 Iris Molecular Diagnostics Inc Homogener nachweis von analyten
CN103091485A (zh) * 2004-11-03 2013-05-08 艾瑞斯国际有限公司 用于亲和分离的微泡
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
AU2012201010B2 (en) * 2005-10-21 2015-01-22 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
AU2007215739B2 (en) * 2006-02-17 2014-01-16 Atsuo Sekiyama Biological load indicator and method of measuring biological load
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
CA2662480C (en) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
CN101557799B (zh) 2006-12-05 2012-08-22 克鲁塞尔荷兰公司 液体抗狂犬病抗体制剂
CN101675075B (zh) 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
NL1033696C2 (nl) * 2007-04-16 2008-10-20 Friesland Brands Bv Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan.
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
HRP20100640T1 (hr) * 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina
WO2009002380A2 (en) * 2007-06-26 2008-12-31 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN103884840A (zh) * 2008-02-21 2014-06-25 艾瑞斯国际有限公司 早期确定前列腺癌治疗后复发的方法
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
PL3456190T3 (pl) * 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
EP2159291A1 (en) 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
US20120020952A1 (en) * 2009-01-26 2012-01-26 Genmab A/S Methods for producing mixtures of antibodies
WO2010089387A1 (en) 2009-02-09 2010-08-12 Morphosys Ag Production of oligoclonal mixtures of immunoglobulins in single cells
AU2010213578B2 (en) 2009-02-12 2015-01-29 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
EP2403531A4 (en) 2009-03-05 2013-02-27 Abbott Lab IL-17 BINDING PROTEINS
JP2012525149A (ja) * 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SI2501817T2 (sl) * 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
KR101539684B1 (ko) 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
PL2606064T3 (pl) * 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN103517921B (zh) 2010-12-21 2017-07-18 Abbvie 公司 IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
WO2012094321A1 (en) 2011-01-03 2012-07-12 Avm Biotechnology, Llc Personalized production of biologics and method for reprogramming somatic cells
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RS59728B1 (sr) * 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) * 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US20130171059A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
IN2014DN08163A (https=) * 2012-03-06 2015-05-01 Regeneron Pharma
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
KR102228296B1 (ko) 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
DK2847231T3 (da) * 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
ES2456823B1 (es) * 2012-09-21 2015-01-27 Consejo Superior De Investigaciones Científicas (Csic) Método de producción de repertorios complejos de moléculas recombinantes
EP3470431A1 (en) * 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
AU2013339038B2 (en) * 2012-11-05 2017-12-21 Zenyaku Kogyo Kabushikikaisha Antibody and antibody composition production method
EP2928919A2 (en) 2012-12-04 2015-10-14 AbbVie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
EP2938634A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Dual specific binding proteins having a receptor sequence
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US9222142B2 (en) * 2013-01-15 2015-12-29 The Regents Of The University Of California Adenoviruses and their use
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
MX373245B (es) 2013-07-05 2020-05-11 Genmab As Anticuerpos cd3 humanizados o quiméricos.
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
MX2016004420A (es) 2013-10-06 2017-03-31 Abbvie Inc Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr.
WO2015084883A2 (en) 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
EP3126384B1 (en) 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
CA2943707A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
MX370807B (es) 2014-07-11 2020-01-08 Genmab As Anticuerpos que se unen a axl.
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP6863888B2 (ja) 2014-10-01 2021-04-21 メディミューン，エルエルシー ポリペプチドをコンジュゲートさせる方法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
CN110655582B (zh) 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
SI3115376T1 (sl) 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
CN108368171A (zh) 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
CN108368172B (zh) 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
RU2018109739A (ru) * 2015-08-27 2019-09-20 Кристал Байосайнс Инк. Трансгенное животное для получения антител, имеющих общую легкую цепь
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
AU2017269115B2 (en) 2016-05-26 2024-06-20 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
SG11201811431VA (en) 2016-07-14 2019-01-30 Genmab As Multispecific antibodies against cd40 and cd137
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
BR112019005895A2 (pt) 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
SG11201903693QA (en) 2016-11-01 2019-05-30 Genmab Bv Polypeptide variants and uses thereof
WO2018098553A1 (en) * 2016-12-01 2018-06-07 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Production of ricin antibodies in plant
SG11201905259SA (en) * 2017-02-02 2019-08-27 Merck Patent Gmbh Preferred pairing of antibody domains
KR20250140128A (ko) 2017-02-10 2025-09-24 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
BR112019018533A2 (pt) 2017-03-09 2020-04-14 Genmab A/S anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, método para tratar uma doença, e, uso de um anticorpo
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
AU2018246872C1 (en) 2017-03-31 2023-05-18 Merus B.V. ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EP3649155A1 (en) 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
EA202090003A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
EA202090005A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3743440A1 (en) 2018-01-24 2020-12-02 Genmab B.V. Polypeptide variants and uses thereof
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3768707A4 (en) * 2018-03-19 2022-01-26 The Invention Science Fund II, LLC COMPOSITIONS AND METHODS FOR MODIFIED B CELLS EXPRESSING REALIZED BIOLOGICAL AGENTS
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
BR112020022179A2 (pt) 2018-05-03 2021-02-02 Genmab B.V. primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit.
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
CN112513074A (zh) 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7534281B2 (ja) 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
MA53122A (fr) 2018-07-13 2021-05-19 Genmab As Variants d'anticorps cd38 et leurs utilisations
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
US20210369842A1 (en) 2018-11-06 2021-12-02 Genmab A/S Antibody formulation
US20220380440A1 (en) 2018-12-31 2022-12-01 Merus N.V. Truncated multivalent multimers
CN113227132A (zh) 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3927745A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
EP3966241A1 (en) 2019-05-09 2022-03-16 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
US20210054049A1 (en) 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021020416A1 (ja) 2019-07-30 2021-02-04 小野薬品工業株式会社 二重特異性抗体
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof
CN114728065A (zh) 2019-11-26 2022-07-08 上海岸迈生物科技有限公司 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
KR20220130724A (ko) 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
CN116407626A (zh) 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
CA3168613A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
WO2021211510A2 (en) * 2020-04-13 2021-10-21 Affyimmune Therapeutics, Inc. Epcam antibody and car-t cells
GB2612450A (en) 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CA3176436A1 (en) 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
MX2022014208A (es) 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
EP4192859A1 (en) 2020-08-06 2023-06-14 BioNTech SE Binding agents for coronavirus s protein
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
IL301085A (en) 2020-09-10 2023-05-01 Genmab As A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
AU2021342342A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
BR112023005742A2 (pt) 2020-10-02 2023-05-02 Genmab As Anticorpo, composição, composição farmacêutica, método para tratar uma doença, ácido nucléico, vetor de expressão, célula, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
JP2023554422A (ja) 2020-12-16 2023-12-27 メルス ナムローゼ フェンノートシャップ がんの治療のための多重特異性抗体
US20240150484A1 (en) 2021-03-12 2024-05-09 Genmab A/S Non-activating antibody variants
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
IL308300A (en) 2021-05-07 2024-01-01 Genmab As PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
JP2024523438A (ja) 2021-06-21 2024-06-28 ジェンマブ エー／エス Ｃｄ１３７結合物質とｐｄ－ｌ１結合物質の組合せ投薬レジメン
KR20240051280A (ko) 2021-09-06 2024-04-19 젠맵 에이/에스 Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
EP4469476A1 (en) 2022-01-25 2024-12-04 Merus N.V. Combination therapy for the treatment of cancer
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
JP2025524728A (ja) 2022-07-15 2025-07-30 フィアン セラピューティクス エルティーディー 抗体－薬物複合体
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
WO2024143442A1 (ja) 2022-12-27 2024-07-04 中外製薬株式会社 会合が制御されたポリペプチド
CN116333103B (zh) * 2023-02-09 2025-10-10 广州国家实验室 抗沙贝病毒属病毒的中和抗体及其制备方法和应用
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
CN121285385A (zh) 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
AR133071A1 (es) 2023-06-30 2025-08-20 Genmab As ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5180502A (ja) 1974-12-28 1976-07-14 Seirei Ind Tsumejikufurikaeshikiseigyakutenkonsochi
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU600885B2 (en) 1984-05-25 1990-08-30 Zymogenetics Inc. Stable DNA constructs
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FI884924A7 (fi) 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
EP0402029B1 (en) 1989-06-08 1994-01-12 The Wistar Institute Monoclonal antibodies for post exposure treatment of rabies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5959177A (en) † 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
CA2075206C (en) † 1989-12-01 2006-05-23 Herbert L. Heyneker Production of recombinant polypeptides by bovine species and transgenic methods
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH0568599A (ja) 1990-07-31 1993-03-23 Wistar Inst 遺伝子工学的に作られた抗体
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US6255458B1 (en) † 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
CA2104598C (en) 1991-03-29 2003-01-07 Justus B. Cohen Methods for selection of recombinant host cells expressing high levels of a desired protein
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2111858A1 (en) 1991-07-15 1993-02-04 James S. Crowe Production of antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) * 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
WO1994023046A1 (en) 1993-04-07 1994-10-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
CA2168202A1 (en) 1993-07-30 1995-03-16 Joseph Dougherty Efficient gene transfer into primary lymphocytes
US5693506A (en) † 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0739412B1 (en) † 1993-12-23 2002-02-27 Infigen, Inc. ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
FR2717187B1 (fr) 1994-03-10 1996-05-31 Transgene Sa Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6080560A (en) † 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
JPH08116978A (ja) 1994-10-18 1996-05-14 Nisshinbo Ind Inc 抗体Ｆａｂライブラリーの作製法
DK0807173T3 (da) * 1994-12-30 2008-01-07 Univ California Fremgangsmåder til fremstilling af immunoglobuliner indeholdende beskyttelsesproteiner i planter og anvendelse deraf
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
GB9621113D0 (en) 1996-10-10 1996-11-27 Univ Southampton Transgenic fish
JP2001505055A (ja) 1996-12-02 2001-04-17 ウエイク・フオレスト・ユニバーシテイ Ｈｉｖ感染の治療としてのｈｉｖコレセプターの不活性化
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
NZ337495A (en) † 1997-03-06 2001-06-29 Infigen Inc Bovine primordial germ cells and their use in cloning
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
CN1303442A (zh) 1997-09-23 2001-07-11 牛津生物医学（英国）有限公司 方法
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
EP0968694B1 (en) 1997-11-26 2004-05-06 Mitsubishi Precision Co., Ltd. Information guidance system
US6074385A (en) 1998-02-03 2000-06-13 Kiefer Corp. Hair follicle devitalization by induced heating of magnetically susceptible particles
JP2002509736A (ja) 1998-03-30 2002-04-02 リサーチ ディベロップメント ファンデーション 副腎皮質刺激ホルモン放出因子レセプター−１欠損マウス
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
CN1241574A (zh) * 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
GB9823930D0 (en) † 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN1345334A (zh) 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
DK2067788T3 (da) 1999-05-18 2015-10-19 Dyax Corp Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
WO2001019394A2 (en) 1999-09-15 2001-03-22 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
JP2003513635A (ja) 1999-11-01 2003-04-15 カイロン コーポレイション 発現ベクター、トランスフェクション系、およびそれらの使用方法
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
DE60038132T2 (de) 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
AU2001245358A1 (en) † 2000-02-29 2001-09-12 Auburn University Production of antibodies in transgenic plastids
EP1284752A4 (en) 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
JP4819285B2 (ja) 2000-05-16 2011-11-24 トーマス・ジェファーソン・ユニバーシティー 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
CN1334343A (zh) * 2000-07-14 2002-02-06 中国医学科学院肿瘤医院肿瘤研究所 抑制肿瘤生长的新抗体、其衍生物及其应用
EP1184458A1 (en) † 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
EP1188771A1 (en) 2000-09-15 2002-03-20 U-BISys B.V. Libraries of human heavy chain variable fragments in a functional format
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
DE60239386D1 (de) 2001-01-25 2011-04-21 Evolva Ltd Zellbibliothek
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2449071C (en) 2001-06-15 2008-12-16 Crucell Holland B.V. Chimaeric phages
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
ATE466941T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
NZ531291A (en) 2001-08-21 2006-02-24 Univ Jefferson Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
KR100968664B1 (ko) 2001-08-27 2010-07-06 제넨테크, 인크. 항체 발현 및 조립을 위한 시스템
EP2022799A2 (en) 2001-11-16 2009-02-11 Biogen Idec Inc. Polycistronic expression of antibodies
WO2003046012A1 (en) 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
NZ532838A (en) 2001-11-30 2008-05-30 Ca Nat Research Council Multimeric complex preferably pentamer molecules derived from the AB5 toxin family i.e. verotoxin and their use in medical treatment
US20030215914A1 (en) 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US20050037427A1 (en) 2001-12-10 2005-02-17 Erwin Houtzager Structure for presenting desired peptide sequences
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
GB2387030A (en) 2002-03-26 2003-10-01 Thales Plc Compensation of mutual coupling in array antenna systems
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
ITGE20020049A1 (it) 2002-06-05 2003-12-05 Ali Spa Dispositivo a pistone per la erogazione di quantitativi dosati di sostanze pastose, quali i gelati, applicabile alle macchine per la loro fa
AU2003243059A1 (en) 2002-06-14 2003-12-31 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
CA2489475C (en) 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
AU2002368062A1 (en) 2002-06-26 2004-01-19 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
AU2003245129B2 (en) 2002-07-10 2008-09-04 Agostino Di Trapani Building block
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2004245429A1 (en) 2003-06-10 2004-12-16 Farallone Holding Bv Binding peptides: methods for their generation and use
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
CN1961002B (zh) 2004-05-27 2011-05-18 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
JP4487068B2 (ja) 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006040322A1 (en) 2004-10-12 2006-04-20 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
EP1812067B1 (en) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20090130652A1 (en) 2005-06-23 2009-05-21 Crucell Holland B.V. Optimization of West Nile Virus Antibodies
US8642513B2 (en) 2005-09-15 2014-02-04 Crucell Holland B.V. Method for preparing immunoglobulin libraries
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2007141274A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2245571B1 (en) 2008-02-05 2019-04-10 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
US20120020952A1 (en) 2009-01-26 2012-01-26 Genmab A/S Methods for producing mixtures of antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
JP2013004215A (ja) 2011-06-14 2013-01-07 Hitachi Ltd リチウムイオン二次電池
JP2016184957A (ja) 2012-02-09 2016-10-20 シャープ株式会社 情報処理装置及び情報処理方法
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers

Also Published As

Publication number Publication date
DK1523496T3 (da) 2011-10-17
NZ537277A (en) 2008-04-30
US9303081B2 (en) 2016-04-05
US20180094289A1 (en) 2018-04-05
US20070054362A1 (en) 2007-03-08
HK1070902A1 (en) 2005-06-30
EP2314629B1 (en) 2013-10-16
CN105884893A (zh) 2016-08-24
DK2314629T4 (da) 2023-02-06
ES2442615T5 (es) 2023-03-16
AU2010249150A1 (en) 2010-12-23
JP2011177193A (ja) 2011-09-15
PT1523496E (pt) 2011-09-29
US20160319320A1 (en) 2016-11-03
EP1523496A2 (en) 2005-04-20
JP2016220696A (ja) 2016-12-28
DK2314629T3 (da) 2014-01-20
ES2368733T3 (es) 2011-11-21
CA2492377A1 (en) 2004-01-29
JP6049239B2 (ja) 2016-12-21
US10934571B2 (en) 2021-03-02
US20070077624A1 (en) 2007-04-05
EP2314629B2 (en) 2022-11-16
AU2003250074A1 (en) 2004-02-09
US20090263864A1 (en) 2009-10-22
JP4836451B2 (ja) 2011-12-14
ATE514717T1 (de) 2011-07-15
US20050170398A1 (en) 2005-08-04
CA2872136C (en) 2017-06-20
JP2014204734A (ja) 2014-10-30
US20130243773A1 (en) 2013-09-19
US7932360B2 (en) 2011-04-26
AU2010249150B9 (en) 2013-12-19
EP2314629A1 (en) 2011-04-27
CN101537180A (zh) 2009-09-23
US7262028B2 (en) 2007-08-28
US20180112247A1 (en) 2018-04-26
AU2003250074B2 (en) 2010-09-09
US7927834B2 (en) 2011-04-19
CN1668636A (zh) 2005-09-14
CA2965865C (en) 2021-10-19
PT2314629E (pt) 2014-01-22
WO2004009618A2 (en) 2004-01-29
JP2006515503A (ja) 2006-06-01
CA2492377C (en) 2015-02-03
CA2965865A1 (en) 2004-01-29
CY1111886T1 (el) 2015-11-04
AU2010249150B2 (en) 2012-10-04
CN100480260C (zh) 2009-04-22
CA2872136A1 (en) 2004-01-29
ES2442615T3 (es) 2014-02-12
EP1523496B1 (en) 2011-06-29
US20110177073A1 (en) 2011-07-21
CN101537180B (zh) 2016-02-10
WO2004009618A3 (en) 2004-11-04
US7429486B2 (en) 2008-09-30
JP6166693B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
SI1523496T1 (sl) Rekombinantno proizvajanje zmesi protiteles
GB0129105D0 (en) Expression control using variable intergenic sequences
IL188094A0 (en) Il-1?? binding antibodies and fragments thereof
ATE490787T1 (de) Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
WO2002016436A3 (en) ANTIBODIES TO HUMAN IL-1$g(b)
WO2007047829A3 (en) Novel heterodimeric proteins and uses thereof
NZ594968A (en) Humanized c-kit antibody
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
PT1930439E (pt) Factores neurotróficos
SG156690A1 (en) Mammalian genes involved in infection
TW200635946A (en) Binding proteins specific for human matriptase
WO2003016501A3 (en) Recombinant antibodies, and compositions and methods for making and using the same
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2003022868A3 (en) Metal binding proteins and associated methods
WO2005047325A3 (en) Monkey immunoglobulin sequences
WO2003040301A3 (en) Cell cycle progression proteins
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
WO2006013462A3 (en) Growth factors nsg28, nsg30, and nsg32
DE60326716D1 (de) Promoter Sequenzen aus Moos und dessen Verwendung
WO2002077023A3 (en) A new essential downstream component of the wingless signalling pathway